Clinical Trial Update: A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) [Phase 3]

View source ↗

Summary

A Phase 3 pediatric study evaluating mirabegron for overactive bladder in participants aged 5 to under 18 was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Overactive Bladder (OAB), Pharmacokinetics of Mirabegron | Phase 3 | Status: TERMINATED | Results posted: 2023-12-28